Cardiff Oncology CFO granted 486,650 stock options

Cardiff Oncology, Inc. reported that Chief Financial Officer Joshua B. Muntner received a grant of 486,650 stock options to purchase common stock at an exercise price of $1.58 per share.

Rhea-AI Filing Summary

Cardiff Oncology, Inc. reported that Chief Financial Officer Joshua B. Muntner received a grant of 486,650 stock options to purchase common stock at an exercise price of $1.58 per share. These options expire on April 6, 2036 and are held directly.

According to the vesting schedule, 121,663 options vest on April 6, 2027, and 10,139 options vest monthly for 36 months after that date. Following this award, Muntner holds a total of 487,150 stock options linked to Cardiff Oncology common stock.

Insights

Equity compensation analyst

CFO receives a sizable, routine stock option grant with long-term vesting.

Chief Financial Officer Joshua B. Muntner was granted 486,650 stock options with a $1.58 exercise price, expiring on April 6, 2036. This is a compensation-related award, not an open-market purchase or sale, so it carries limited trading signal.

The options vest over time, with 121,663 vesting on April 6, 2027 and 10,139 vesting monthly for 36 months thereafter. This multi-year schedule is designed to align the CFO’s incentives with longer-term company performance, while spreading potential dilution over several years.

Insider Trade Summary

Grant/Award: 486,650 shares

Grant/Award 1 txn

Insider Muntner Joshua B

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Options	486,650	$0.00	$0.00

Holdings After Transaction: Stock Options — 487,150 contracts (Direct)

Footnotes (1)

1. F1. 121,663 vest on April 6, 2027 and 10,139 vest monthly for 36 months thereafter.

Key Figures

Options granted: 486,650 options Exercise price: $1.58 per share Options post-transaction: 487,150 options +3 more

6 metrics

Options granted 486,650 options Stock options awarded on April 6, 2026

Exercise price $1.58 per share Exercise price for granted stock options

Options post-transaction 487,150 options Total stock options held after grant

Initial vesting tranche 121,663 options Vesting on April 6, 2027

Monthly vesting amount 10,139 options Vest monthly for 36 months after April 6, 2027

Option expiration April 6, 2036 Expiration date of granted options

Key Terms

Stock Options, exercise price, expiration date, vest, +1 more

5 terms

Stock Options financial

"security_title: Stock Options"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

exercise price financial

"conversion_or_exercise_price: 1.5800"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-04-06T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vest financial

"121,663 vest on April 6, 2027 and 10,139 vest monthly"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Cardiff Oncology (CRDF) disclose about its CFO in this Form 4/A?

Cardiff Oncology disclosed a new stock option grant to its CFO. Chief Financial Officer Joshua B. Muntner received 486,650 stock options with a $1.58 exercise price, expiring in 2036, as part of his equity compensation rather than an open-market share purchase or sale.

How many Cardiff Oncology (CRDF) stock options were granted to the CFO?

The CFO received 486,650 stock options linked to common stock. These options give him the right to buy 486,650 Cardiff Oncology shares at a fixed $1.58 exercise price, subject to the vesting schedule and the April 6, 2036 expiration date disclosed.

What is the exercise price and expiration date of the CRDF options granted?

The granted options have a $1.58 exercise price and expire in 2036. Specifically, the stock options let the CFO purchase Cardiff Oncology common shares at $1.58 per share, with the options expiring on April 6, 2036 if they are not exercised before that date.

How do the new CRDF stock options vest for Cardiff Oncology’s CFO?

The options vest over several years starting in 2027. Cardiff Oncology disclosed that 121,663 options vest on April 6, 2027, and an additional 10,139 options vest each month for 36 months afterward, creating a long-term incentive structure for the CFO.

How many Cardiff Oncology (CRDF) stock options does the CFO hold after this grant?

After the grant, the CFO holds 487,150 stock options in total. The Form 4/A shows this post-transaction figure, indicating his aggregate option position tied to Cardiff Oncology common stock following the 486,650-option award.

Is the CRDF Form 4/A transaction a market buy or sell of Cardiff Oncology shares?

No, this transaction is an option grant, not a market trade. The filing characterizes it as a grant or award acquisition of stock options, so it reflects equity compensation rather than the CFO buying or selling Cardiff Oncology shares on the open market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/16/2026 - 08:07 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Muntner Joshua B

(Last) (First) (Middle)

11055 FLINTKOTE AVENUE

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cardiff Oncology, Inc. [ CRDF ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
04/16/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$1.58	04/06/2026		A		486,650		(1)	04/06/2036	Common Stock	486,650	$0	487,150	D

Explanation of Responses:

1. 121,663 vest on April 6, 2027 and 10,139 vest monthly for 36 months thereafter.

	/s/ Joshua Muntner	04/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)